COPD Trial, Recruiting NCT03890224 Sponsor: Clinact Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT03890224
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with COPD at a severe stage (classified as GOLD C or D) with lung function below a certain level (FEV1 less than 65%)
  • People who have recently had an episode of serious breathing difficulties with too much carbon dioxide in the blood (a condition called acute hypercapnic respiratory failure), which required breathing support — either through a mask or a breathing tube — for more than 24 hours
  • People who, between 48 hours and 2 weeks after that breathing support was stopped, still show elevated carbon dioxide levels in the blood while resting during the day without breathing assistance (or with limited oxygen only if removing it entirely causes oxygen levels to drop dangerously low)

Who may not be able to join:

  • People who are currently using a home breathing support device (NIV or CPAP) on an ongoing basis
  • People whose main lung condition is a restrictive lung disease (such as obesity-related breathing problems or chest wall disease) — though there may be exceptions if the breathing problem is considered primarily obstructive by the treating doctor (confirm with trial site)
  • People with a BMI (body mass index) over 35
  • People taking sedative or pain medications at higher levels — specifically more than three sedating drugs or more than 20mg of morphine per day
  • People who have been diagnosed with severe obstructive sleep apnoea (more than 30 breathing interruptions per hour during sleep, using French diagnostic criteria)
  • People whose thinking or memory difficulties would prevent them from giving informed consent to participate
  • People who are pregnant
  • People with a smoking history of fewer than 10 pack-years (a measure of how much a person has smoked over their lifetime)
  • People with a psychiatric illness requiring antipsychotic medication, those currently in treatment for drug or alcohol addiction, or those without a fixed home address after leaving hospital
  • People with an unstable heart condition affecting the coronary arteries
  • People under 18 years of age
  • People who would be unable to follow the trial's requirements and schedule
  • People whose life expectancy is less than 12 months due to a condition other than COPD
  • People who spent more than 10 days in intensive care during their recent hospital stay
  • People who are not covered by national health insurance
  • People who are under a legal protection arrangement such as guardianship or wardship

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jesus Gonzalez, MD, Hôpital Pitié Salpêtrière-Charles Foix, Paris, France ,

Phone: +33-180-13-15-19

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Clinact
Registry
ClinicalTrials.gov
Start date
4 July 2019
Est. completion
15 June 2024

Where this trial is recruiting

🇫🇷 France

Primary endpoints

admission-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov